Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial by Prince, H Miles, Prof, Kim, Youn H, Prof, Horwitz, Steven M, MD, Dummer, Reinhard, Prof, Scarisbrick, Julia, MD, Quaglino, Pietro, Prof, Zinzani, Pier Luigi, Prof, Wolter, Pascal, MD, Sanches, Jose A, PhD, Ortiz-Romero, Pablo L, Prof, Akilov, Oleg E, MD, Geskin, Larisa, MD, Trotman, Judith, MD, Taylor, Kerry, MBBS, Dalle, Stephane, Prof, Weichenthal, Michael, Prof, Walewski, Jan, Prof, Fisher, David, MD, Dréno, Brigitte, Prof, Stadler, Rudolf, Prof, Feldman, Tatyana, MD, Kuzel, Timothy M, Prof, Wang, Yinghui, MS, Palanca-Wessels, Maria Corinna, MD, Zagadailov, Erin, PharmD, Trepicchio, William L, PhD, Zhang, Wenwen, PhD, Lin, Hui-Min, PhD, Liu, Yi, PhD, Huebner, Dirk, MD, Little, Meredith, MPH, Whittaker, Sean, Prof, Duvic, Madeleine, Prof

Get full text